Ulrich Bothe, Judith Günther, Reinhard Nubbemeyer, Holger Siebeneicher, Sven Ring, Ulf Bömer, Michaele Peters, Alexandra Rausch, Karsten Denner, Herbert Himmel, Andreas Sutter, Ildiko Terebesi, Martin Lange, Antje M Wengner, Nicolas Guimond, Tobias Thaler, Johannes Platzek, Uwe Eberspächer, Martina Schäfer, Holger Steuber, Thomas M Zollner, Andreas Steinmeyer, Nicole Schmidt
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate inflammatory processes. Here, we describe the discovery of two clinical candidate IRAK4 inhibitors, BAY1834845 (zabedosertib) and BAY1830839 , starting from a high-throughput screening hit derived from Bayer's compound library. By exploiting binding site features distinct to IRAK4 using an in-house docking model, liabilities of the original hit could surprisingly be overcome to confer both candidates with a unique combination of good potency and selectivity...
January 16, 2024: Journal of Medicinal Chemistry